Filing identity and period
The supplied filing is Transgenomic, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012—not a filing identified as Precipio, Inc. It reports second-quarter and six-month results for 2012, with comparisons to 2011.
Business context and key financial metrics
Transgenomic operated clinical laboratories, pharmacogenomics services, and diagnostic tools businesses, including WAVE instruments and related consumables.
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Net sales | $9.093 million, up 19% from $7.667 million | $16.299 million, up 8% from $15.148 million |
| Gross profit / margin | $4.562 million / 50%, versus $4.555 million / 59% | $7.666 million / 47%, versus $8.742 million / 58% |
| Operating loss | $1.370 million, versus $1.624 million | $3.809 million, versus $2.374 million |
| Net loss | $0.563 million, versus $5.998 million | $3.259 million, versus $8.776 million |
| Net loss available to common stockholders | $0.728 million, versus $6.265 million | $3.589 million, versus $9.303 million |
| Operating cash flow | Not presented separately for the quarter | Cash used of $5.197 million, versus $0.087 million provided |
At June 30, 2012, cash and cash equivalents were $6.297 million and short-term U.S. Treasury investments were $8.994 million. Working capital was $14.062 million, compared with $0.870 million at December 31, 2011. Total debt was approximately $7.406 million, including $6.061 million current and $1.345 million long-term; the filing separately records a $5.5 million PGx prepayment obligation as a current liability. Total liabilities were $19.349 million. The company reported no material off-balance-sheet arrangements.
Material changes and drivers
- Six-month sales rose 8% overall: clinical laboratory sales increased 20%, pharmacogenomics services declined 23%, and diagnostic tools sales were approximately flat.
- Despite higher sales, six-month gross margin fell to 47% from 58%. Management cited New Haven laboratory system repair and backlog-processing costs, test mix, lower consumables sales, and instrument mix.
- The New Haven laboratory information management system failure reduced first-quarter processing capacity and shifted some revenue into the second quarter. The company said the issue was resolved in late April and processing capacity restored.
- Second-quarter net loss improved substantially, in part because of a $1.0 million non-cash gain from remeasuring warrant liability and because 2011 included a large preferred-stock-related expense. The six-month operating loss nevertheless widened.
- In February, the company completed a private placement with approximately $17.4 million net proceeds, issuing 19 million shares and warrants for 9.5 million shares; $3.0 million of related-party convertible notes also converted. Common shares outstanding increased to 71.646 million from 49.626 million at year-end.
Outlook, risks, and contingencies
Management anticipated continued 2012 growth across all three businesses but gave no quantitative revenue or earnings guidance. It highlighted Medicare coverage for the C-GAAP test, new assay and product launches, the A. Menarini distribution relationship, and European CE IVD registration as growth opportunities. Management said available liquidity should cover expected cash needs for at least 12 months, while cautioning that ongoing losses, sales execution, expense reduction, or access to additional capital could affect longer-term liquidity.
The company had paid $1.2 million toward the $5.5 million PGx prepayment obligation and said PGx had not responded to its outreach about arranging payment; it intended to comply with the note. Other risks include possible future laboratory processing disruptions, reimbursement and customer-funding uncertainty, competition, and foreign-exchange exposure. The company did not hedge foreign currency risk and said a hypothetical 10% exchange-rate change could materially affect future results. Ordinary-course claims were not expected by management to have a material adverse effect. Firm vendor commitments were $3.0 million.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Transgenomic, Inc., not Precipio, Inc.
- Reconcile the filing’s executive-summary statement that six-month sales “decreased” 8% with the financial statements and detailed MD&A, which show sales increased 8%.
- Review the $5.5 million PGx prepayment obligation, its timing, and how it relates to reported debt and current liabilities.
- Assess cash burn and the company’s 12-month liquidity assertion against the $5.197 million first-half operating cash outflow and future funding needs.
- Track gross-margin recovery, laboratory-system reliability, clinical reimbursement, and whether new products and distribution arrangements generate sustained sales.
- Evaluate dilution and the potential impact of outstanding warrants, including the Level 3 warrant liability and its valuation assumptions.